— Know what they know.
Not Investment Advice

CLDI AMEX

Calidi Biotherapeutics, Inc.
1W: -4.4% 1M: -19.4% 3M: -55.0% YTD: -94.3% 1Y: -95.9% 3Y: -100.0%
$1.08
+0.00 (+0.00%)
 
Weekly Expected Move ±11.3%
$1 $1 $1 $1 $1
AMEX · Healthcare · Biotechnology · Tech Score Sell · Power 26 · $2.8M mcap · 3M float · 11.91% daily turnover · Short 19% of daily vol

Balance Sheet Trends

Total Assets
$9M -37.5% ▼
5Y CAGR: +36.8%
Total Liabilities
$5M -58.3% ▼
5Y CAGR: -26.8%
Shareholders Equity
$4M +145.0% ▲
Cash & Investments
$6M -41.6% ▼
5Y CAGR: +67.9%
Total Debt
$2M -72.1% ▼
5Y CAGR: -30.0%
Net Debt
-$4M -42.3% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$2M$372K$2M$10M$6M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$2M$372K$2M$10M$6M
Net Receivables$0$0$1M$0$0
Inventory$0$0$0$0$0
Other Current Assets$100K$303K$125K$249K$656K
Total Current Assets$3M$786K$4M$10M$6M
Property, Plant & Equip.$585K$1M$5M$3M$2M
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$230K$129K$119K
Other Non-Current Assets$66K$725K$143K$892K$800K
Total Non-Current Assets$651K$2M$6M$4M$3M
Total Assets$3M$3M$10M$14M$9M
— Liabilities —
Accounts Payable$624K$2M$3M$2M$613K
Short-Term Debt$5M$5M$807K$3M$2M
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$17M$30M$0$2K$2M
Total Current Liabilities$26M$43M$10M$9M$4M
Long-Term Debt$0$0$2M$600K$600K
Other Non-Current Liab.$0$10M$3M$128K$115K
Total Non-Current Liabilities$43K$10M$8M$3M$1M
Total Liabilities$26M$53M$18M$12M$5M
— Equity —
Common Stock$2K$2K$4K$2K$1K
Retained Earnings-$45M-$70M-$100M-$122M-$142M
Accumulated OCI-$1K-$14K-$47K-$28K-$13K
Total Stockholders Equity-$23M-$50M-$8M$2M$4M
Total Liabilities & Equity$3M$3M$10M$14M$9M
— Key Metrics —
Total Debt$5M$6M$7M$7M$2M
Net Debt$3M$6M$5M-$3M-$4M
Total Investments$0$0$230K$129K$119K

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms